Advances in Clinical Chemistry 1st Edition by Gregory S Makowski ISBN 012374797X 9780123747976

Advances in Clinical Chemistry 1st Edition by Gregory S Makowski – Ebook PDF Instant Download/Delivery: 012374797X, 9780123747976
Full download Advances in Clinical Chemistry 1st Edition after payment

Product details:

ISBN 10: 012374797X 
ISBN 13: 9780123747976
Author: Gregory S Makowski

Volume 48 in the internationally acclaimed Advances in Clinical Chemistry contains chapters submitted from leading experts from academia and clinical laboratory science. Authors are from a diverse field of clinical chemistry disciplines and diagnostics ranging from basic biochemical exploration to cutting-edge microarray technology.

• Leading experts from academia and clinical laboratory science
• Volume emphasizes novel laboratory advances with application to clinical laboratory diagnostics and practical basic science studies

Advances in Clinical Chemistry 1st Table of contents:

Chapter 1: Caspases in Myocardial Infarction
1. Abstract
2. Introduction
3. Apoptosis and the Heart
4. Caspases
5. Activation of Caspases
5.1. Extrinsic (Death Receptor) Pathway of Caspase Activation
5.2. Intrinsic (Mitochondrial) Pathway of Caspase Activation
6. Activation of Caspases in the Heart
7. Functional Significance of Caspases
7.1. Role of Caspases During Embryonal Development
7.2. Role of EVector Caspases During Apoptosis
8. Caspases for Detection of Apoptosis
8.1. Techniques for Detection of Caspases
8.2. Comparison of Techniques for Detection of Caspases to TUNEL Method
9. Apoptosis and Caspases in MI
9.1. Morphological Features of Apoptotic Cardiomyocytes
10. Apoptosis of Cardiomyocytes in Ventricular Remodeling After MI
11. Apoptosis of Other Cell Types in the Evolution of Fibrous Scar
12. Anti-Caspase Treatment
13. Conclusion
References
Chapter 2: Deamidated Gliadin Peptides as Targets for Celiac Disease-Specific Antibodies
Abbreviations
1. Abstract
2. Introduction
3. Prolamins as Cereal Storage Proteins
4. Pathogenesis of CD
5. Serological Diagnosis of CD
6. Gliadin Antibodies of CD Patients Recognize Deamidated Gliadin
7. Enhanced Diagnostic Potential of Glutamine-Glutamic Acid Substituted Gliadin-Analogous Peptides
8. Does Epitope Specificity of Gliadin Antibodies of CD Patients Mirror Substrate Specificity of tTG
9. Relation Between B- and T-Cell Epitopes of Gliadin
10. Conclusions
References
Chapter 3: Urokinase Receptor Variants in Tissue and Body Fluids
Abbreviations
1. Abstract
2. Introduction
2.1. Full-Length, Glycolipid-Anchored uPAR, uPAR(I-III)
2.2. Cleavage of uPAR(I–III)
2.3. Shedding of uPAR Forms
3. Monoclonal Antibodies to uPAR
4. Immunoassays for the Quantification of uPAR
5. uPAR in Cancer
5.1. Breast Cancer
5.2. Colorectal Cancer
5.3. Lung Cancer
5.4. Prostate Cancer
5.5. Gynecologic Cancer
5.6. Leukemia
6. Other Diseases
7. Conclusions and Perspectives
Acknowledgements
Refenences
Chapter 4: Proteomics in Cancer
1. Abstract
2. Introduction
2.1. Clinical Background for Proteomic Studies in Cancer
3. Sampling for Proteomic Analysis
3.1. Cell Lines
3.2. Whole Tissue Biopsies
3.3. Purified Tumor Cells
3.4. Body Fluids
4. Proteomic Technologies Used in Cancer Proteomics
4.1. 2D-PAGE
4.2. Differential In-Gel Electrophoresis
4.3. Isotope-Coded Affinity Tagging and Amino Acid-Coded Mass Tagging
4.4. Gel-Free Technologies
4.5. Targeted Glycoproteomics
4.6. Reverse-Phase Protein Arrays-Based Studies
4.7. Antibody-Based Proteomic Studies
4.8. Combinatorial Beads
5. Proteomic Applications in Cancer
5.1. Expression Proteomic Studies
5.2. Functional Proteomic Studies
6. What Has Been Achieved in Cancer Proteomics?
6.1. Understanding Cancer
6.2. Screening and Diagnosis
6.3. Prognosis
6.4. Therapy
7. Conclusion
References
Chapter 5: Paraneoplastic Neurological Syndromes And Onconeural Antibodies: Clinical And Immunologic
1. Abstract
2. Introduction
3. Onconeural Antigens
4. Paraneoplastic Syndromes of the CNS
4.1. Paraneoplastic Encephalomyelitis
4.2. Focal Encephalitis
4.3. Extrapyramidal Disorders
4.4. Paraneoplastic Cerebellar Degeneration
4.5. Paraneoplastic Opsoclonus–Myoclonus
4.6. Visual Syndromes
4.7. Spinal Cord Disorders
4.8. Stiff-Person Syndrome
5. PNS of the Peripheral Nervous System
5.1. Sensory Neuronopathy
5.2. Autonomic Neuropathy
5.3. Acute and Chronic Sensory and Motor Neuropathies
5.4. Neuropathy Associated with Paraproteinemic Disorders
6. Paraneoplastic Nervous System Syndromes of the Neuromuscular Junction
7. Diagnosis of Paraneoplastic Nervous System Syndromes
7.1. Diagnostic Criteria
7.2. Paraclinical Investigations
7.3. Detection of Onconeural Antibodies
7.4. Seronegative Paraneoplastic Nervous System Syndromes
8. Pathogenesis of Paraneoplastic Nervous System Syndromes
8.1. Tumors
8.2. Humoral Immune Response
8.3. Cellular Immune Response
9. Therapy for Paraneoplastic Nervous System Syndromes
10. Future Aspects
References
Chapter 6: Pathophysiological Mechanisms of Angiogenesis
Abbreviations
1. Abstract
2. Introduction
2.1. Angiogenesis, Vasculogenesis, and Lymphangiogenesis.
2.2. Beneficial and Harmful Angiogenesis
3. Measuring the Angiogenic Process
3.1. Quantity Vs Quality of Angiogenesis
4. Endothelial Cells and the Initiation of Angiogenesis
4.1. VEGF as A Prototypical Direct-Acting Angiogenic Factor
4.2. VEGF and Its Receptors
4.3. VEGF Signal Transduction During Angiogenesis
4.4. Autocrine Production of Angiogenic Factors by Endothelial Cells
5. Differential Angiogenic Pathways
5.1. Angiogenic Factor Expression in Malignant Tumors
5.2. Consequences of DiVerential Angiogenesis in Tumors.
5.3. Host Tissue Angiogenic Responses.
5.4. Vascular Phenotype
5.5. Plasticity of Angiogenic Pathways
6. Impact of the Vessel’s Environment on Angiogenesis
7. Angiogenesis Biomarkers for Assessing Human Disease
7.1. Vascular Density
7.2. Imaging
7.3. Angiogenic Factor Expression
7.4. Circulating Biomarkers
8. Therapeutic Targeting of Angiogenesis
9. Conclusion
References
Chapter 7: Bikunin (Urinary Trypsin Inhibitor): Structure, Biological Relevance, And Measurement
Abbreviations
1. Abstract
2. Introduction
2.1. Protein Synthesis and Release
2.2. Molecular Structure
3. Roles in Biological Processes
3.1. Role in Inflammation
3.2. Bik in Cell Signaling
3.3. Bik in Apoptosis
4. Diagnostic Testing
5. Pathophysiology of Bik
5.1. Normal Populations
5.2. Pregnancy
5.3. Infection
5.4. Cancer
5.5. Surgery
5.6. Kidney Diseases
5.7. Vascular Disease and Coagulation
5.8. Diabetes
6. Summary
References
Chapter 8: Gene Expression Assays
1. Abstract
2. Introduction
3. The Technology
3.1. Manufacturing Arrays
3.2. Laser Capture Microdisection and Linear Amplification of RNA
3.3. Hybridization and Data Analysis
3.4. Limitations
4. Gene Expression Assays in Cancer
4.1. Gene Expression Assays in Breast Cancer
4.2. Gene Expression Assays in Other Cancers
4.3. Considerations When Comparing Array Studies
5. Applications of Arrays to Neurological Disorders
5.1. Huntington’s Disease
5.2. Multiple Sclerosis
5.3. Alzheimer’s Disease
5.4. Motor Neuron Disease
5.5. Expression Profiling Other Neurological Disorders
6. Application of Microarrays to Neuropsychiatric Disorders
6.1. Schizophrenia and Bipolar Disorder
6.2. Major Depressive Disorder
7. Future Advances

People also search for Advances in Clinical Chemistry 1st:

advances in clinical chemistry impact factor
    
advances in clinical chemistry pdf
    
advances in clinical chemistry elsevier
    
advances in clinical chemistry journal
    
advances in clinical chemistry abbreviation

Tags: Gregory S Makowski, Clinical Chemistry